Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colonic Neoplasms, Esophageal Neoplasms, Kidney Neoplasms, Recurrence, Stomach Neoplasms

NCT04636775 2023-12-11

Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)

Unknown

46 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT04813068 2021-05-28

Lung Cancer Patients' Attitudes to a Second Course of Radiotherapy

Unknown

30 enrolled

Thoracic

Lung Neoplasms, Recurrence

NCT04797702 2021-03-15

CT32

Phase 1/2 Unknown

67 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT04292119 2021-03-10

Lorlatinib Combinations in Lung Cancer

Phase 1/2 Unknown

96 enrolled

Thoracic

Lung Neoplasms, Recurrence

NCT04768491 2021-02-24

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

Unknown

82 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT04492969 2020-07-31

Prospective Observation of Failure Patterns in NSCLC Treated With ICIs

Unknown

320 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT03613753 2020-02-05

Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer

Phase 2 Unknown

72 enrolled

Thoracic

Recurrence, Small Cell Lung Carcinoma

NCT03029273 2019-01-17

NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC

Phase 1 Unknown

20 enrolled

Thoracic

Lung Neoplasms, Recurrence

NCT02281708 2014-11-03

Multicenter Randomized Controlled Trial Adjuvant Chemotherapy vs Observation in pStage Ib Lung Adenocarcinoma

Phase 3 Unknown

1,012 enrolled

Thoracic

Lung Neoplasms, Recurrence

Clinical Trials

JIVAN

Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)

Lung Cancer Patients' Attitudes to a Second Course of Radiotherapy

CT32

Lorlatinib Combinations in Lung Cancer

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

Prospective Observation of Failure Patterns in NSCLC Treated With ICIs

Irinotecan Plus Lobaplatin Versus Irinotecan in the Second-line Treatment of Small Cell Lung Cancer

NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC

Multicenter Randomized Controlled Trial Adjuvant Chemotherapy vs Observation in pStage Ib Lung Adenocarcinoma